Entest BioMedical has signed a letter of intent to acquire Therinject. Therinject is involved with Cancer Research, marker testing/development and ‘bead’ formation used in vaccine development.
The company said that once a definitive agreement is in place, Therinject will become a wholly-owned subsidiary of Entest BioMedical.
David Koos, chairman of Bio-Matrix Scientific Group, said: “Entest BioMedical has already established a joint venture with Therinject and Bio-Matrix Scientific Group. I believe this is an obvious natural fit and removes any potential conflicts between each company’s goals.”
Steven Joseph, managing principal of Therinject, said: “I have been involved with new develops taking place at Entest for some time. I’m excited that Therinject will become an Entest company. I believe we are doing some extremely important work in cancer treatment, COPD and potentially Multiple Sclerosis. With the linking of these companies together, we should get further in our research at a much faster pace.”
Entest BioMedical is a majority-owned subsidiary of Bio-Matrix Scientific Group and is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses.